EDIT Editas Medicine
- 6.020
- +0.510+9.26%
- 6.010
- -0.010-0.17%
Editas Medicine News
EVP, Chief Financial Officer Erick Lucera Sells 22,337 Shares of Editas Medicine Inc (EDIT)
Form 144 | Editas Medicine(EDIT.US) Officer Proposes to Sell 256.95K in Common Stocks
SEC FILLINGS DISCLOSED/ May 17, $Editas Medicine(EDIT.US)$ Officer Lucera Erick intends to sell 45,000 shares of its common stock on May 17, with a total market value of approximately $256.95K. Sou
Director Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (EDIT)
On May 13, 2024, Jessica Hopfield, Director at Editas Medicine Inc (NASDAQ:EDIT), purchased 45,000 shares of the company, as reported in the SEC Filing.
Editas Medicine(EDIT.US) Director Buys US$253.87K in Common Stock
$Editas Medicine(EDIT.US)$ Director Hopfield Jessica purchased 45,000 shares of common stock on May 13, 2024 at an average price of $5.6415 for a total value of $253.87K.Source: Announcement What is s
Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing
Jessica Hopfield, Director, on May 13, 2024, executed a purchase for 45,000 shares in Editas Medicine (EDIT) for $253,868.
Editas Medicine to Present Clinical Data From the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster
Editas Medicine, Inc. (NASDAQ:EDIT) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Editas Medicine, Inc. (NASDAQ:EDIT) missed earnings with its latest quarterly results, disappointing overly-optimistic forecasters. Statutory earnings fell substantially short of expectations, wi
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Editas Medicine Preclinical Data Highlights Advancement of in Vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Research includes the first-ever application of AsCas12a in vivo, optimized LNP delivery, and gene editing RNA guide modifications Data to support development of the Company's in vivo gene editing medicines pipeline
Buy Rating Affirmed for Editas Medicine Amid Promising CRISPR Pipeline and Growth Potential
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript
Express News | Citigroup Maintains Buy on Editas Medicine, Lowers Price Target to $15
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
Clinical-stage biotech Editas Medicine (NASDAQ: EDIT) delivered quarterly results that fell well short of expectations on Wednesday.
Editas Medicine Price Target Announced at $7.00/Share by Morgan Stanley
Editas Medicine Price Target Announced at $7.00/Share by Morgan Stanley
Editas Medicine Is Maintained at Equal-Weight by Barclays
Editas Medicine Is Maintained at Equal-Weight by Barclays
Editas Medicine Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 74.76% Barclays $11 → $9 Maintains Equal-Weight 02/29/2024 210.68% Citigroup $11 → $16 Maintain
Editas Medicine Upgraded at J.P. Morgan on Recent Weakness
Express News | Editas Medicine Inc : Barclays Cuts Target Price to $9 From $11
Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight
Editas Medicine (EDIT) has an average outperform rating and a price target range of $7 to $27, according to analysts polled by Capital IQ. Price: 5.21, Change: +0.18, Percent Change: +3.53
Editas Medicine's Innovative In Vivo Gene Editing Approach and Positive Clinical Trial Prospects Bolster Buy Rating
Analysis
Price Target
No Data
